pTau-217 (AD-Detect)
A blood biomarker of Alzheimer's-related brain pathology — specifically tau protein phosphorylation associated with amyloid burden.
One of the most significant advances in blood testing in years. Until recently, detecting Alzheimer's pathology required a PET scan or spinal tap. pTau-217 correlates strongly with brain amyloid and can detect changes years before symptoms.
The guideline does not endorse testing cognitively unimpaired or asymptomatic people, and that is the sentence that matters for anyone considering ordering this from a longevity panel. The accuracy figures above were established in people who already had objective cognitive impairment; applied to a population where amyloid pathology is far less common, the same test produces a much higher share of false positives. There is no optimal p-tau217 value, there are assay-specific cut-points, and a positive result in someone without symptoms currently changes no treatment decision while changing a great deal else.
What did your pTau-217 result indicate?
What to do next. This is a research-grade metric moving into clinical use, and thresholds are assay-specific enough that comparing across labs is unreliable. A concerning result belongs with a neurologist rather than with a supplement plan. The modifiable risk factors remain the highest-value response in every result category: blood pressure, glucose, sleep, hearing, exercise and social engagement.
What pTau-217 (AD-Detect) actually measures — the analyte, and the assay
What is being measured is one phosphate group on one amino acid. Tau is a microtubule-associated protein carrying dozens of possible phosphorylation sites. Phosphorylation at threonine 217 changes early in amyloid-related pathology, and a small fraction of the modified protein escapes into blood. The test detects that specific modified form, not tau in general.
The concentrations are near the edge of what is measurable. Plasma p-tau217 sits in the low picograms per milliliter, orders of magnitude below its cerebrospinal fluid concentration, which is why the assays are ultrasensitive platforms — single-molecule arrays, high-sensitivity chemiluminescent immunoassays, or immunoprecipitation followed by mass spectrometry — rather than ordinary immunoassays.
Some laboratories report a ratio instead, and the ratio behaves better. Expressing phosphorylated tau217 as a percentage of total tau217 cancels out anything that changes both together. The evidence for that is direct: modeling a fall in filtration rate from an eGFR of 60 to 45 in amyloid-negative participants produced calculated increases of +31% and +55% in two raw p-tau217 assays and only +19% in the percentage form Bornhorst 2025.
Absolute values do not transfer between platforms. Two laboratories measuring the same plasma report different numbers, so every published cut-point belongs to the assay that generated it and to no other.
pTau-217 (AD-Detect): what changes the blood, and what only changes the reading
What changes the p-tau217 in your blood:
- Amyloid pathology in the brain. This is the signal the assay was built for, and in a memory-clinic-like cohort of 202 participants, 114 (56%) were amyloid-PET positive Bornhorst 2025 — which is the prevalence figure the rest of this page keeps coming back to.
- Kidney function, which moves it a great deal. In the same cohort 86 of 202 (43%) had stage 3 to 4 chronic kidney disease, and the effect of reduced filtration on the measured concentration was large enough to require quantifying Bornhorst 2025. Cut-offs for amyloid pathology have since been examined explicitly against kidney function, body mass index and anemia Yun 2026.
- Body mass, through plasma volume. A larger circulating volume dilutes a brain-derived protein arriving at a fixed rate, which lowers the concentration without lowering the pathology Yun 2026.
- Age, which correlates with both the pathology and the filtration rate and therefore contributes twice.
- Amyloid-independent factors in general, which have been separated from amyloid-dependent ones as a distinct source of variability in plasma Alzheimer biomarkers Lee 2024.
What changes only the reading:
- How the sample was handled between the needle and the freezer. Pre-analytical factors have been shown to change the performance of plasma phospho-tau217 Bali 2024, and the delay before processing specifically changes how well plasma p-tau217 and its ratio detect brain amyloidosis Delaby 2025. A protein present at picogram concentrations adsorbs to plastic and degrades in ways a nanogram-level analyte never notices.
- Which tube. Plasma and serum are different matrices for this analyte, and tube material matters at these concentrations Bali 2024.
- Freeze-thaw cycles, each of which costs signal.
- Which platform ran it, and therefore which cut-point applies. The two raw assays in the filtration analysis responded differently to the same physiological change — +31% against +55% Bornhorst 2025.
- Whether you are reading a concentration or a percentage. They are not interchangeable and the percentage is the more stable of the two Bornhorst 2025.
- Hemolysis, which contributes protein and phosphatase activity the assay did not plan for.
Reference interval or decision threshold — which kind of number pTau-217 (AD-Detect) is
These are decision thresholds, tied to a comparator test rather than to a healthy population. A p-tau217 cut-point is chosen by asking which value best separates people who are amyloid-positive on PET or cerebrospinal fluid from people who are not, at a sensitivity and specificity somebody selected. It is not the edge of a normal band.
Most laboratories now use two thresholds and an indeterminate zone between them. Below the lower value the result is treated as unlikely to indicate amyloid pathology, above the upper value as likely, and in between as not answering the question. That middle band exists because a single line forces every borderline person into one of two wrong answers.
The arithmetic that nobody prints is the one that matters most. Predictive value depends on how common the target is in the population tested. In a cohort where 56% were amyloid-positive Bornhorst 2025, a positive result is highly informative. Apply the same threshold to a well 50-year-old with no cognitive symptoms, where the prevalence is a small fraction of that, and the proportion of positive results that are correct falls sharply — not because the assay got worse, but because Bayes' theorem does not care how good the assay is.
Cut-points have already been revised for physiology. Work explicitly adjusting p-tau217 cut-offs for kidney function, body mass index and anemia Yun 2026 exists because a single fixed threshold misclassifies people whose plasma differs for reasons unrelated to their brain.
How you would know your pTau-217 (AD-Detect) was wrong — and when to redraw
The pathology accumulates over years, so the retest interval is measured in years too. Amyloid deposition is a slow process. A meaningful change in plasma p-tau217 driven by pathology takes 12 months or more to appear, which means a repeat at three or six months is measuring the laboratory rather than the brain.
Conditions that must match: the same assay on the same platform, the same tube type and handling protocol, a comparable filtration rate, and comparable body mass Bali 2024 Bornhorst 2025 Yun 2026.
How you would know a change was not about your brain:
- Draw an eGFR or Cystatin-C at the same sitting, every time. A 15-point fall in filtration rate can move a raw p-tau217 by 31% to 55% with no change in pathology Bornhorst 2025. If the biomarker rose and the filtration rate fell, the kidney is the more likely explanation.
- Ask for the percentage form if the platform offers it, since it absorbed less than half the filtration effect the raw assays did Bornhorst 2025.
- Ask how long the sample sat before processing. Preanalytical delay changes detection performance measurably Delaby 2025.
- Check whether body weight changed substantially between the two draws Yun 2026.
- The confirmatory tests are not blood tests. Amyloid PET and cerebrospinal fluid analysis are the comparators the cut-points were built against, and whether either is appropriate is a decision for a clinician, not a consequence of a number.
What pTau-217 (AD-Detect) cannot tell you
It is a marker of amyloid pathology, not of dementia, and the distinction is the whole of the caution on this page. Amyloid pathology is present in people with no symptoms and absent in people with cognitive complaints from other causes. The assay measures a protein modification; it does not measure memory, function or future.
It cannot give a timeline. Nothing in a p-tau217 result states when, whether, or how fast anything would happen. Any reading that supplies one has been supplied by the reader.
It cannot diagnose anything. A blood biomarker sits inside a clinical assessment that includes history, cognitive testing, examination and often imaging. This page explains what the number is and what moves it; it does not tell anybody what they have, and a result of any value should be discussed with a physician before it is acted on.
It cannot be compared with a friend's result, a published mean, or a previous result from a different laboratory, because absolute values are platform-specific Bornhorst 2025.
It cannot be separated from the kidney without measuring the kidney. That is a hard limitation and the reason a filtration estimate belongs on the same requisition Bornhorst 2025 Yun 2026.
The wrong inference readers actually draw is that a positive result in an asymptomatic person is an early diagnosis. In a low-prevalence group most positive results are not confirmed by the comparator test, and the source of variability that produced the positive is as likely to be amyloid-independent as amyloid-dependent Lee 2024.
Sources read for these sections
- Bornhorst JA, et al. Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations. Neurology 2025 · PMID 39823562
- Yun J, et al. Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia. JAMA Neurology 2026 · PMID 41627837
- Bali D, et al. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Alzheimer's Research and Therapy 2024 · PMID 38331843
- Delaby C, et al. Impact of preanalytical delay on the performance of plasma Abeta42, Abeta42/40, p-tau217, and p-tau217/Abeta42 in detecting brain amyloidosis in the ALZAN cohort. Alzheimer's and Dementia 2025 · PMID 41166452
- Lee EH, et al. Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors. Alzheimer's and Dementia 2024 · PMID 39535473
Where to start with pTau-217 (AD-Detect)
In this order. Start at the supplement and you learn nothing, because you never established the number was real.
You have the range, where it came from and the first two moves. Inside is the rest of the five-pathway protocol — supplements, hormones, peptides — the order to run them in, and what to change when the number will not move.
Get the full protocol — $10/mo →📚 Palmqvist S et al., JAMA 2020 — plasma p-tau217 for Alzheimer's discrimination. Livingston G et al., Lancet 2024 — modifiable dementia risk factors.
🩸 Test your pTau-217 (AD-Detect)
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 103 markers →What pTau-217 (AD-Detect) is usually tested alongside
One marker is a data point. These panels add the markers that make pTau-217 (AD-Detect) interpretable, name why each is on the list, and load the set into your cart at 10% off.
includes this + 8 more markers — Family history of dementia, noticeable memory change, or you want the earliest possible read on brain health while there's still time to act.
What people use pTau-217 (AD-Detect) to decide
Nobody orders a test for its own sake. pTau-217 (AD-Detect) is on the test list for these pathways — each one links to what the pathway claims, and what its test list is read for before you spend anything on it.
Fog with no attention deficit and no mood change is often immune rather than neurotransmitter. Raised inflammatory markers point at this pathway; a clean panel argues you should be looking somewhere else on this page.
Would you feel it? Symptoms pTau-217 (AD-Detect) helps explain
People search for how they feel, not for a marker. These are the complaints where this one is worth checking, and whether it is first-line or a follow-up.
Why your pTau-217 (AD-Detect) might be wrong
Most abnormal results are interference, not disease. Check these before you change anything. Each says whether the number is wrong (repeat it), badly timed (redraw it), or real with a cause.
Both affect plasma concentrations of the tau and amyloid markers independently of brain pathology — a real limitation of blood-based neurodegeneration testing.
Interpret with kidney function in mind, and with a clinician.
These assays are sensitive to tube type, processing delay and freeze-thaw.
Use a lab that runs the validated workflow. Do not compare across platforms.
What pTau-217 (AD-Detect) means in combination
One marker tells you a little; combinations tell you the story. These are the named patterns this one takes part in.
Genuinely reassuring, and worth stating because the genotype alone frightens people. ε4 raises lifetime risk; a normal pTau-217 says the amyloid pathology those risk figures describe is not currently detectable. Many ε4 carriers never develop dementia.
Put the effort into the fourteen modifiable risk factors — hearing, blood pressure, glucose, exercise, sleep, alcohol, social connection. They account for far more than the genotype does, and unlike it they respond.
What to test next
These put pTau-217 (AD-Detect) in context — each with its own full breakdown.
Frequently asked questions
Assay- and lab-specific reference values. Ranges vary by laboratory and assay — always compare to the range printed on your own report.
Low/negative. Alzheimer's Association Clinical Practice Guideline on blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease, 2025.
Suggests amyloid pathology — should be interpreted by a physician, ideally with neurology input. It is not a standalone diagnosis.
Reassuring.
You can order pTau-217 (AD-Detect) directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.
Where this goes next
This page is the free framework. The protocol itself — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.